Corixa Corp. won an appeal against an FDA decision issued earlier this year that required additional clinical trials in order to market the cancer drug Bexxar. (BioWorld Today)

Corixa Corp. won an appeal against an FDA decision issued earlier this year that required additional clinical trials in order to market the cancer drug Bexxar. (BioWorld Today)

BioCryst Pharmaceuticals Inc. stopped development of its lead drug candidate, peramivir, on poor preliminary data from a Phase III influenza study. (BioWorld Today)

BioCryst Pharmaceuticals Inc. stopped development of its lead drug candidate, peramivir, on poor preliminary data from a Phase III influenza study. (BioWorld Today)